viernes, 27 de noviembre de 2009

Novartis, Sanofi - Aventis: Malaria...? No es terapia para pobres.

Nearly a million people die from malaria each year because they can’t afford the most effective treatment and instead often buy old drugs to which the malaria parasite has become resistant, according to a study of six high-risk nations by Populations Services International Malaria, Reuters writes.

Artemisinin combination therapy, or ACT, drugs made by firms such as Novartis and Sanofi-Aventis can cost as much as 65 times the daily minimum wage in some African countries.

The meds can cost up to $11 to patients buying over the counter, while older drugs to less effective drugs cost just $0.30 cents. (Ver...)


With most people accessing anti-malarial medication through the private sector, price becomes a critically important barrier,” PSI director Desmond Chavasse tells Reuters. “A full course of an adult treatment of ACT can be up to 65 times the minimum daily wage.”

Ver Daniel Vasella Malaria Memento

No hay comentarios: